Abstract
Background:
Methanogens are associated with gut dysmotility in animal models but have not been robustly studied in humans. The WMC assesses regional transit time (TT) and pH in the GI tract.
Aims:
To study the segmental TT and pH among patients with SIBO or IMO utilizing WMC.
Methods:
We conducted a retrospective study of 207 patients who underwent a glucose or lactulose breath test (BT) and WMC from 2010–2022. Diagnosis of SIBO and IMO were based on the 2017 North American consensus criteria. TT and pH were extracted from WMC recordings. We tested for differences in means of continuous variables and frequencies of categorical variables using two-sample t-tests, Wilcoxon Rank Sum test, Chi-square, and Fisher exact tests. We used R version 3.3.1 (2016-06-21) for all statistical analyses.
Results:
A total of 196 patients met criteria, mean age 47.4 years, 155 (79.1%) females. Of the 86 (43.9%) patients with a positive BT, 42 (58.3%) had IMO only (meeting only CH4 criteria) and 30 (34.9%) met both H2 and CH4 criteria. Colonic TT was longer in patients with a positive BT compared to negative patients (40h:29min vs 28h:51min, p=0.028). Small bowel TT and colonic TT were longer in patients with IMO compared to negative patients (SBTT: 5h:15min vs 4hr:32min, p=0.021; CTT: 44hr:23min vs 28hr:51min, p=0.030). There were no significant differences in segmental pH compared to negative patients.
Conclusions:
To our knowledge, this is the largest study of patients who have undergone both BT and WMC. A positive BT was associated with delayed CTT, while having IMO only was associated with both delayed CTT and SBTT, but neither with pH. Future investigation is needed to elucidate whether changes in intestinal microbiota affect gut transit.
Keywords: small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), breath test (BT), wireless motility capsule (WMC)
BACKGROUND
Small intestinal bacterial overgrowth (SIBO) refers to the clinical condition in which changes to the small intestine microbiota, namely an increase in number or change in composition of microorganisms, lead to gastrointestinal (GI) symptoms including bloating, diarrhea and abdominal discomfort1–5. There are many well-established risk factors for SIBO, including anatomic changes, dysmotility and gastric hypochlorhydria6–10. The mainstay of treatment focuses on correction of the underlying cause and administration of antibiotics with the goal to restore a healthy and diverse microbiome, and thus alleviating symptoms2,3,6,11.
More recently, intestinal methanogen overgrowth (IMO), grouped under SIBO, became its own entity as the microbiology, pathophysiology, symptoms, diagnosis and treatment differ from patients with SIBO. IMO refers to overgrowth of methanogens resulting in elevated levels of methane. The association between methanogens, methane and dysmotility has been well established as many prior studies have found that methanogen positivity on a breath test (BT) is positively correlated with constipation and prolonged transit time (TT). This is a key difference between IMO and SIBO in that predominant symptoms for patients with IMO include constipation which is associated with prolonged colonic transit time (CTT) 12–18, both not seen in classic SIBO. Give these differences, treatment of IMO to address underlying causes, as well as methanogens, should differ significantly from SIBO treatment.
The wireless motility capsule (WMC) is an orally ingested recording device that enables assessment of segmental GI transit through validated patterns in pressure, pH and temperature19,20. The WMC has been approved for evaluation of delayed gastric emptying, chronic idiopathic constipation, and diffuse dysmotility, allowing for one to study the association of intestinal dysmotility with SIBO and IMO. Most prior studies have assessed dysmotility based on markers of motility, such as alterations in the migrating motor complex, while few have truly assessed TT8–10,21,22.
In addition to dysmotility, gastric hypochlorhydria, frequently due to proton pump inhibitors, has been shown to be associated with SIBO23–26. For example, a recently published, prospective study found the incidence of SIBO to be 7.8% in asymptomatic, healthy volunteers after administration of pantoprazole for just 7 days27. One hypothesized mechanism is the loss of stomach acidity leading to unregulated growth of harmful, microorganisms that usually are unable to survive the caustic environment. This finding is well illustrated in the literature, however the relationship between SIBO or IMO and changes in small intestine or colonic pH has yet to be elucidated. The microbiota and pH have a bidirectional relationship: microbial metabolites affect intestinal pH which in turn influence microbiota diversity and fermentation production28,29. Not only is there a significant change in the number of bacteria, but rRNA gene sequencing has shown that the bacterial composition significantly differs in patients with SIBO than those without SIBO30,31. Given this, it is quite plausible that intestinal pH could significantly alter the microbiota leading to SIBO or, alternatively, be affected by dysbiosis and microbial metabolites thus acting as another marker for SIBO.
Our study aims to assess the relationship of SIBO and IMO with data collected from WMC, namely pH and transit times, in different segments throughout the GI tract.
MATERIALS AND METHODS
Patient Population
This was a retrospective study of patients greater than 18 years of age who underwent both a glucose or lactulose BT and WMC at Stanford University Hospital from 2010–2022. The substrate utilized (glucose or lactulose) for breath testing was based on the discretion of the ordering provider. Laxatives, probiotics, prokinetics, anticholinergics or any other medications that alter motility were stopped 24 hours prior to the test. Antibiotics were stopped one month prior to the test.
Patients were diagnosed with SIBO and IMO based on the hydrogen (H2) and methane (CH4) criteria from The 2017 North American Consensus32. A rise in H2 of ≥ 20 p.p.m. from baseline by 90 min during either a glucose or lactulose BT was considered a positive test for H2 criteria. A CH4 level ≥ 10 p.p.m. during any part of the glucose or lactulose BT was considered a positive test for CH4 criteria.
Using these criteria, patients were divided into different strata based on diagnostic criteria for H2 and CH4. Patients in the BT positive group (i.e. the broader diagnosis of SIBO) met H2 and/or CH4 criteria, and the IMO group met CH4 criteria only without H2 criteria. Patients who did not meet H2 or CH4 criteria were considered BT negative patients.
Data
We used the Stanford Research Repository (STARR), a clinical database that serves as a repository for all clinical data generated at Stanford for research purposes, to identify eligible participants. Demographic information including date of birth, age, gender, race and ethnicity as well as the dates and results from the BT and WMC were collected from STARR. Primary symptoms, comorbidities and medications were obtained by chart review in the electronic medical record at Stanford University Hospital. These three variables were extracted from the clinic note written by the Gastroenterologist at the time that the first diagnostic test, either BT or WMC, was ordered.
WMC recordings were reanalyzed by one author to obtain more granular detail, including low, median and high pH values, mean pressure and motility index. All variables were collected in each of the following GI segments: stomach, antrum, duodenum, small bowel and colon. Gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small and large bowel transit time (SLBTT) and whole gut transit time (WGTT) were also recollected to ensure accuracy of the times reported in the initial WMC results. This study was approved by the Institutional Review Board of Stanford University.
Statistical Analysis
We used R version 3.3.1 (2016-06-21) to perform all statistical analyses. For BT positive and BT negative groups, we computed descriptive statistics of continuous variables and frequencies for categorical variables. To test for differences across in TT variables across positive and negative BT, we used the Wilcoxon Rank Sum test. We used the two-sample t-tests for other continuous variables where the distribution was approximately normal. We used Chi-square tests for categorical variables and proportions tests for dichotomous categorical variables. For categorical variables with less than five observations in a cell, we used the Fischer exact test. A significance threshold of 0.05 was used for all tests.
For co-morbid diagnoses that have been previously identified as possible risk factors or predisposing conditions for SIBO, we created dummy variables that take the value 1 in the presence of the comorbid condition and 0 otherwise. Proportion tests were used to test for differences in the frequency of these conditions across the two groups.
RESULTS
Clinical Characteristics
The study population consisted of 207 patients who underwent both a WMC study and either a glucose or lactulose BT. Eleven patients had a high baseline H2, thus they were excluded as the tests were uninterpretable. This resulted in a total of 196 patients included in our analysis.
Mean age of the study population was 47.4 years and 155 (79.1%) were females. Of the 196 patients, 120 (61.2%) underwent a glucose BT, 67 (34.2%) lactulose BT and 9 (4.6%) had both completed. There were 110 (56.1%) patients who had a negative BT, and 86 (43.9%) patients met H2 and/or CH4 criteria and thus were considered BT positive. Of those with positive tests, 42 (58.3%) had IMO only, meaning they met CH4 criteria only. Demographic results for overall BT positive patients and IMO only patients, can be seen in Tables 1 and 2, respectively. Older age (>65) and tobacco use were significantly more prevalent among patients with a positive BT (p=0.013 and p=0.011, respectively) and IMO only (p=0.038 and p=0.048), respectively, when compared to negative patients. The distribution of primary GI symptoms was significantly different in patients with IMO compared to negative patients (p=0.036), constipation and bloating being more prevalent (Supplemental Table A and B).
Table 1.
Comparison of baseline demographics and clinical characteristics of patients with a positive BT, defined by those meeting H2 and/or CH4 criteria, to those without.
| Characteristics | Total (N=196) | BT positive (N=86) | BT negative (N=110) | P value (comparison of SIBO vs BT negative) |
|---|---|---|---|---|
| Age > 65 | 38 (19.4%) | 24 (27.9%) | 14 (12.7%) | 0.013* |
|
| ||||
| Female | 155 (79.5%) | 66 (76.7%) | 89 (81.7%) | 0.507 |
|
| ||||
| Tobacco Use | 28 (14.3%) | 19 (22.1%) | 9 (8.2%) | 0.011* |
|
| ||||
| Marijuana Use | 23 (11.7%) | 11 (12.8%) | 12 (10.9%) | 0.855 |
|
| ||||
| PPI Use | 77 (39.3%) | 29 (33.7%) | 48 (43.6%) | 0.207 |
|
| ||||
| Prior abdominal surgery | 79 (40.3%) | 39 (45.3%) | 40 (36.4%) | 0.260 |
|
| ||||
| Comorbidities: | ||||
| Gastroparesis | 13 (6.6%) | 4 (4.7%) | 9 (8.2%) | 0.395 |
| Pancreatitis | 5 (2.6%) | 2 (2.3%) | 3 (2.7%) | 1.000 |
| Crohn’s | 3 (1.5%) | 2 (2.3%) | 1 (0.9%) | 0.583 |
| Hiatal Hernia | 8 (4.1%) | 6 (7.0%) | 2 (1.8%) | 0.141 |
| Gastritis | 4 (2.0%) | 1 (1.2%) | 3 (2.7%) | 0.633 |
| Diabetes | 12 (6.1%) | 6 (7.0%) | 6 (5.5%) | 0.888 |
| Ehlers’s Danlos | 16 (8.2%) | 4 (4.7%) | 12 (10.9%) | 0.125 |
| Hypothyroidism | 26 (13.3%) | 12 (14.0%) | 14 (12.7%) | 0.969 |
BT denotes breath test, PPI proton pump inhibitor. All values are written as the following: number of patients (percent of patients).
Table 2.
Comparison of baseline demographics and clinical characteristics of patients with IMO only, defined by those meeting CH4 criteria only, to those without.
| Characteristics | Total (N=152) | IMO only (N=42) | BT negative (N=110) | P value (comparison of IMO only vs BT negative) |
|---|---|---|---|---|
| Age > 65 | 26 (17.1%) | 12 (28.6%) | 14 (12.7%) | 0.038* |
|
| ||||
| Female | 119 (78.3%) | 30 (71.4%) | 89 (81.7%) | 0.248 |
|
| ||||
| Tobacco Use | 18 (11.8%) | 9 (21.4%) | 9 (8.2%) | 0.048* |
|
| ||||
| Marijuana Use | 18 (11.8%) | 6 (14.3%) | 12 (10.9%) | 0.768 |
|
| ||||
| PPI Use | 63 (41.4%) | 15 (35.7%) | 48 (43.6%) | 0.482 |
|
| ||||
| Prior abdominal surgery | 58 (38.2%) | 18 (42.9%) | 40 (36.4%) | 0.582 |
|
| ||||
| Comorbidities: | ||||
| Gastroparesis | 9 (5.9%) | 0 (0.0%) | 9 (8.2%) | 0.063 |
| Pancreatitis | 5 (3.3%) | 2 (4.8%) | 3 (2.7%) | 0.617 |
| Crohn’s | 1 (0.7%) | 0 (0.0%) | 1 (0.9%) | 1.000 |
| Hiatal Hernia | 3 (2.0%) | 1 (2.4%) | 2 (1.8%) | 1.000 |
| Gastritis | 4 (2.6%) | 1 (1.4%) | 3 (2.7%) | 1.000 |
| Diabetes | 8 (5.3%) | 2 (4.8%) | 6 (5.5%) | 1.000 |
| Ehlers’s Danlos | 14 (9.2%) | 2 (4.8%) | 12 (10.9%) | 0.352 |
| Hypothyroidism | 18 (11.8%) | 4 (9.5%) | 14 (12.7%) | 0.781 |
BT denotes breath test, PPI proton pump inhibitor. All values are written as the following: number of patients (percent of patients).
Transit Time Results
CTT was significantly longer in patients with any positive breath test (meeting H2 and/or CH4 criteria) relative to negative patients (40h:29min vs 28h:51min, p=0.028, Figure 1). SLBTT was also significantly longer in patients with any positive breath test compared to negative patients (46hr:59min vs 34hr:48min, p=0.036). There was no statistically significant difference in SBTT in patients with a positive BT compared to BT negative patients. In IMO only positive patients, SBTT, CTT and SLBTT were longer compared to negative patients (SBTT: 5h:15min vs 4hr:32min, p=0.021; CTT: 44hr:23min vs 28hr:51min, p=0.030; SLBTT: 48hr:17min vs 34hr:48min, p=0.031; Figure 2). In addition, GET was shorter in IMO only positive patients compared to negative patients (3hr:00min vs 3hr:41min, p=0.019). WGTT was not significantly different in any positive breath test or IMO positive patients compared to BT negative patients.
Figure 1.

Differences in intestinal transit times between patients with any positive breath test (H2 and/or CH4) compared to patients with negative breath tests
GET: gastric emptying time, SBTT: small bowel transit time, CTT: colonic transit time, SLBTT: small/large bowel transit time, WGTT: whole gut transit time
* Indicates a statistically significant level of 5%
Figure 2.

Differences in intestinal transit times between patients with IMO only (CH4) compared to patients with negative breath tests
GET: gastric emptying time, SBTT: small bowel transit time, CTT: colonic transit time, SLBTT: small/large bowel transit time, WGTT: whole gut transit time
* Indicates a statistically significant level of 5%
pH Results
In assessing for differences in segmental pH between BT positive and BT negative patients, no significant differences were found in the stomach, antrum, duodenum, small intestine or colon (Figure 3).
Figure 3.

Differences in intestinal pH between patients with any positive breath test (H2 and/or CH4) compared to patients with negative breath tests
BT denotes breath test
DISCUSSION
Dysmotility, as measured by alterations in markers of motility such as the migrating motor complex, is frequently reported as a risk factor for the development of SIBO and IMO, however, few studies have assessed the direct association with transit time9,22,33. The current study found significantly longer SBTT and CTT in patients with IMO only compared to those without, as well as significantly longer CTT in any breath test positive patient. To our knowledge, this is the first study to find prolonged SBTT and CTT in patients with IMO using the WMC and is one of few studies where BT results are subdivided by hydrogen and methane criteria. The association between dysmotility and methanogens has been well established. Many previous studies have found a positive correlation between methanogen positivity on a BT, prolonged transit time and symptoms of constipation12–17. For example, a recent retrospective study of 78 patients who underwent both a lactulose BT and whole gut transit scintigraphy found a significant delay in SBTT and CTT in patients meeting CH4 criteria compared to patients meeting H2 criteria (mean accumulated tracer 71.5% vs 44.1%, p<0.05; mean geometric center 4.4 vs 3.1, p<0.01, respectively)17 consistent with our results. There are some data in both animals and humans to support methane directly disturbing intestinal motility, possibly by acting as a neurotransmitter34,35. One unexpected finding was a shorter GET in IMO patients compared to BT negative patients. To our knowledge this has not been described in previous studies. In both IMO and BT negative patients, the GET was within normal limits for both groups. Further studies are needed to shed more light on this finding.
Given the findings of both delayed SBTT and CTT in patients with IMO, as well as the proposed mechanisms for dysmotility, additional treatments including prokinetics aimed at addressing constipation could improve symptoms in patients with IMO compared to or instead of antibiotics alone. WMC could aid in identifying patients who indeed have prolonged TT and thus could respond to additional therapy besides antibiotics. Therapies with prokinetic properties that could be considered include prucalopride or pyridostigmine. These agents could serve as an alterative or adjunct to antibiotic therapies. The role of prokinetics in treating and preventing IMO need to be further investigated.
The current study found an association between any positive BT and prolonged CTT but not SBTT on WMC. Prolonged CTT in SIBO is a new finding but likely reflects the current study population in which 83.7% of patients with SIBO met CH4 criteria and thus likely had underlying physiology similar to patients with IMO only. The lack of association between SIBO and prolonged SBTT has previously been found. A recent retrospective study of 78 patients found no difference in SBTT between BT positive patients and BT negative patients using whole gut transit scintigraphy (62.1% vs 58.6%, p=0.63)17. Similarly, another retrospective study of patients with Parkinson’s found no relationship between SBTT and SIBO (p=0.5)36. However, these findings differ from three studies by Roland et al. illustrating prolonged SBTT in patients with SIBO. They conducted two retrospective cohort studies of patients who underwent both a WMC and lactulose BT. SBTT was significantly longer in patients with SIBO than patients without (n=23; 5.82h vs 3.81h, p=0.05 and n=34; 6.6h vs 4.2h, p=0.04)37,38. These were followed by a prospective study where 30 patients with suspected SIBO underwent a lactulose BT, small bowel aspirate and WMC study. Again, SBTT was significantly longer in SIBO vs non-SIBO patients (10h vs 1.1h, p=0.004)39. These conflicting results could be due to a few differences between the studies. The current sample size was much larger than prior studies and the sample size included more female and older aged patients. In addition, different cutoffs were used when interpreting BTs. Prior studies considered baseline H2 > 10 p.p.m., baseline CH4 >7 p.p.m. or an increase of CH4 ≥ 12 p.p.m. by 90 minutes as positive tests. Further, the reasons for ordering the tests and the time interval between completion of both tests was extremely variable. Thus, changes in treatment or disease state after one test could impact the results of the other test. At this time, further, prospective studies are needed to determine if there are truly transit time alterations in patients with SIBO which could affect treatment decisions.
Many studies have assessed the relationship between gastric pH and SIBO, however, few have assessed intestinal pH. In the studies completed by Roland et al. discussed above, results regarding small intestinal pH varied depending on the study. In one of the retrospective studies, mean small bowel pH was not significantly different in patients with SIBO when compared to those without38. Whereas there was a significant difference in mean small bowel pH in the prospective study (7.01 for SIBO vs 6.49 for non-SIBO, p=0.002)39. The current study revealed no significant differences in intestinal pH between patients with SIBO or IMO than those without. Negative results are unsurprising as pH is driven by several factors including hormones, diet, medications and microbial metabolites, to name a few. Despite the challenges in identifying pathogenic changes in intestinal pH, it remains an essential property of the environment imposing selective pressures on microbial communities, which in turn, influences host physiology and health40. Given the paucity of data, future research is needed to determine if there are indeed intestinal pH differences in patients with SIBO so future therapeutics can be developed to restore the normal pH and healthy microbiome.
In the current study, history of tobacco use and age were significantly associated with SIBO and IMO. Tobacco use is a known risk factor for many GI diseases; however, prior studies have had varied results regarding the association between tobacco and SIBO41–43. Some mechanisms by which cigarette smoke influences microbiota composition include direct antimicrobial effects, alteration of immune homeostasis and mucin production, changes in duodenal pH and prolonged GET to name a few44–47. A recent prospective study assessed the impact of smoking on mucosa-associated microbiota in patients undergoing upper GI endoscopy. Both current and previous smoking was associated with reduced diversity, however, total density of bacteria present was unchanged48. With the positive association between tobacco use and SIBO found in this study, combined with the known effects of cigarettes on the microbiome, it is likely that tobacco use is indeed associated with SIBO and could have more of a causative relationship.
Consistent with prior studies, the current study shows that age > 65 years is associated with SIBO and IMO. Age has been well described as a risk factor for SIBO, likely through several mechanisms including changes in intestinal motility and acid secretion as well as increasing comorbidities and polypharmacy in older age. Though there are some negative studies, the overwhelming majority do show an association between age and SIBO6,43,49.
Given the retrospective nature of our study, there are a few limitations. The cohort of patients came from a single, tertiary center with a specific motility clinic and was a relatively small sample size, thus making the results potentially less generalizable to the average patient. However, in comparison to prior studies, the current study included 196 patients which is significantly more than prior sample sizes (n=23, 30, 34) evaluating transit time and intestinal pH with a WMC in patients with SIBO37–39. Another limitation is that a comparison against healthy controls was not performed. In addition, our data was collected through chart review, and so we are unable to determine if the patients properly prepared for the BT and WMC based on the recommended standards. For example, prior to the BTs, patients should avoid antibiotics within 4 weeks, promotility agents within 1 week and fermentable foods the day before the test2,32. Furthermore, patients had variable timing between WMC and BT studies, and some patients underwent different treatments between the two tests. This could be better controlled for in a prospective study. Lastly, there are many imperfections with BTs, although this is currently the most widely used diagnostic test for SIBO.
CONCLUSIONS
To our knowledge, this is the largest study of patients who have undergone a BT and WMC study. IMO was associated with both delayed SBTT and CTT, but not changes in pH. SIBO was associated with delayed CTT, but not SBTT or changes in pH. These findings show the importance of differentiating IMO from the broader diagnosis of SIBO, as these clinical entities have different microbiota changes and effects on the GI system, and thus patients could potentially benefit from different treatments. It is unclear whether alterations in intestinal microbiota affect gut transit, or rather changes in transit influence the microbiota present. Further investigation is needed to elucidate the cause and effect of this relationship to help drive further therapeutics for SIBO and IMO.
Supplementary Material
Grant support:
SPS was supported by K08 DK134856
Funding:
No funding was used for this study.
Footnotes
Financial disclosures: No financial disclosures exist for all authors.
DECLARATIONS
Consent to participate: Not applicable given the retrospective nature of the study.
Consent to publish: Not applicable given the retrospective nature of the study.
Conflict of interest: No conflict of interest exists for all authors.
Competing interests: No competing interest exists for all authors.
Ethics approval:
- The retrospective chart review study involving human participants was in accordance with the ethical standards of the institution and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standard. The Human Investigation Committee (IRB) of Stanford University approved this study.
- Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies.
Data availability:
The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in a controlled access data storage.
REFERENCES
- 1.Bushyhead D, Quigley EMM. Small Intestinal Bacterial Overgrowth-Pathophysiology and Its Implications for Definition and Management. Gastroenterology. 2022;163(3):593–607. doi: 10.1053/j.gastro.2022.04.002 [DOI] [PubMed] [Google Scholar]
- 2.Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol 2020;115(2):165–178. doi: 10.14309/ajg.0000000000000501 [DOI] [PubMed] [Google Scholar]
- 3.Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020;159(4):1526–1532. doi: 10.1053/j.gastro.2020.06.090 [DOI] [PubMed] [Google Scholar]
- 4.Adike A, DiBaise JK. Small Intestinal Bacterial Overgrowth: Nutritional Implications, Diagnosis, and Management. Gastroenterology Clinics of North America. 2018;47(1):193–208. doi: 10.1016/j.gtc.2017.09.008 [DOI] [PubMed] [Google Scholar]
- 5.Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010;16(24):2978–2990. doi: 10.3748/wjg.v16.i24.2978 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Rao SSC, Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin Transl Gastroenterol 2019;10(10):e00078. doi: 10.14309/ctg.0000000000000078 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Brechmann T, Sperlbaum A, Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study. World Journal of Gastroenterology. 2017;23(5):842–852. doi: 10.3748/wjg.v23.i5.842 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao S. Dysmotility and ppi use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther 2013;37(11):1103–1111. doi: 10.1111/apt.12304 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower Frequency of MMC Is Found in IBS Subjects with Abnormal Lactulose Breath Test, Suggesting Bacterial Overgrowth. Dig Dis Sci 2002;47(12):2639–2643. doi: 10.1023/A:1021039032413 [DOI] [PubMed] [Google Scholar]
- 10.Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The Interdigestive Motor Complex of Normal Subjects and Patients with Bacterial Overgrowth of the Small Intestine. J Clin Invest 1977;59(6):1158–1166. doi: 10.1172/JCI108740 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Rezaie A, Pimentel M, Rao SS. How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. Curr Gastroenterol Rep 2016;18(2):8. doi: 10.1007/s11894-015-0482-9 [DOI] [PubMed] [Google Scholar]
- 12.El Oufir L, Flourié B, Bruley des Varannes S, et al. Relations between transit time, fermentation products, and hydrogen consuming flora in healthy humans. Gut 1996;38(6):870–877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Attaluri A, Jackson M, Valestin J, Rao SSC. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 2010;105(6):1407–1411. doi: 10.1038/ajg.2009.655 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Roccarina D, Lauritano EC, Gabrielli M, Franceschi F, Ojetti V, Gasbarrini A. The role of methane in intestinal diseases. Am J Gastroenterol 2010;105(6):1250–1256. doi: 10.1038/ajg.2009.744 [DOI] [PubMed] [Google Scholar]
- 15.Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel M. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci 2011;56(6):1612–1618. doi: 10.1007/s10620-011-1590-5 [DOI] [PubMed] [Google Scholar]
- 16.Konstantinos Triantafyllou CC, Pimentel M. Methanogens, Methane and Gastrointestinal Motility. J Neurogastroenterol Motil 2014;20(1):31–40. doi: 10.5056/jnm.2014.20.1.31 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Suri J, Kataria R, Malik Z, Parkman HP, Schey R. Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit. Medicine (Baltimore). 2018;97(21):e10554. doi: 10.1097/MD.0000000000010554 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.DuPont AW, Jiang ZD, Harold SA, et al. Motility abnormalities in irritable bowel syndrome. Digestion. 2014;89(2):119–123. doi: 10.1159/000356314 [DOI] [PubMed] [Google Scholar]
- 19.Saad RJ, Hasler WL. A Technical Review and Clinical Assessment of the Wireless Motility Capsule. Vol 7.; 2011:795. [PMC free article] [PubMed] [Google Scholar]
- 20.Tran K, Brun R, Kuo B. Evaluation of regional and whole gut motility using the wireless motility capsule: Relevance in clinical practice. Therapeutic Advances in Gastroenterology. 2012;5(4):249–260. doi: 10.1177/1756283X12437874 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Lee A, Baker J, Hasler WL. GI Motility Testing: Stomach, Small Bowel, and Colon. Journal of Clinical Gastroenterology. 2019;53(3):159. doi: 10.1097/MCG.0000000000001138 [DOI] [PubMed] [Google Scholar]
- 22.Husebye E, Skar V, Høverstad T, Iversen T, Melby K. Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology. 1995;109(4):1078–1089. doi: 10.1016/0016-5085(95)90565-0 [DOI] [PubMed] [Google Scholar]
- 23.Weitsman S, Celly S, Leite G, et al. Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes. Dig Dis Sci 2022;67(1):224–232. doi: 10.1007/s10620-021-06857-y [DOI] [PubMed] [Google Scholar]
- 24.Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol 2018;53(1):27–36. doi: 10.1007/s00535-017-1371-9 [DOI] [PubMed] [Google Scholar]
- 25.Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8(6):504–508. doi: 10.1016/j.cgh.2009.12.022 [DOI] [PubMed] [Google Scholar]
- 26.Lo W, Chan WW. Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis. Clinical Gastroenterology and Hepatology. 2013;11(5):483–490. doi: 10.1016/j.cgh.2012.12.011 [DOI] [PubMed] [Google Scholar]
- 27.Durán-Rosas C, Priego-Parra BA, Morel-Cerda E, et al. Incidence of Small Intestinal Bacterial Overgrowth and Symptoms After 7 Days of Proton Pump Inhibitor Use: A Study on Healthy Volunteers. Dig Dis Sci 2024;69(1):209–215. doi: 10.1007/s10620-023-08162-2 [DOI] [PubMed] [Google Scholar]
- 28.Ratzke C, Gore J. Modifying and reacting to the environmental pH can drive bacterial interactions. PLoS Biology 2018;16(3). doi: 10.1371/journal.pbio.2004248 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wu L, Wang W, Wu Z, et al. Effect of acid and alkali stress on extracellular metabolite profile of Lactobacillus plantarum ATCC 14917. Journal of Basic Microbiology. 2020;60(8):722–729. doi: 10.1002/jobm.202000203 [DOI] [PubMed] [Google Scholar]
- 30.Leite G, Morales W, Weitsman S, et al. The duodenal microbiome is altered in small intestinal bacterial overgrowth. PLoS ONE. 2020;15(7 July). doi: 10.1371/journal.pone.0234906 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Li J, Zhang R, Ma J, et al. Mucosa-Associated Microbial Profile Is Altered in Small Intestinal Bacterial Overgrowth. Frontiers in Microbiology. 2021;12. doi: 10.3389/fmicb.2021.710940 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology. 2017;112(5):775–784. doi: 10.1038/ajg.2017.46 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The Interdigestive Motor Complex of Normal Subjects and Patients with Bacterial Overgrowth of the Small Intestine. doi: 10.1172/JCI108740 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Jahng J, Jung IS, Choi EJ, Conklin JL, Park H. The effects of methane and hydrogen gases produced by enteric bacteria on ileal motility and colonic transit time. Neurogastroenterol Motil 2012;24(2):185–190, e92. doi: 10.1111/j.1365-2982.2011.01819.x [DOI] [PubMed] [Google Scholar]
- 35.Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 2006;290(6):G1089–1095. doi: 10.1152/ajpgi.00574.2004 [DOI] [PubMed] [Google Scholar]
- 36.Su A, Gandhy R, Barlow C, Triadafilopoulos G. Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson’s disease who present with functional gastrointestinal symptoms. BMJ Open Gastroenterol 2017;4(1):e000132. doi: 10.1136/bmjgast-2017-000132 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Roland BC, Ciarleglio MM, Clarke JO, et al. Small Intestinal Transit Time Is Delayed in Small Intestinal Bacterial Overgrowth.; 2014. www.jcge.com [DOI] [PubMed] [Google Scholar]
- 38.Roland BC, Ciarleglio MM, Clarke JO, et al. Low ileocecal valve pressure is significantly associated with small intestinal bacterial overgrowth (SIBO). Digestive Diseases and Sciences. 2014;59(6):1269–1277. doi: 10.1007/s10620-014-3166-7 [DOI] [PubMed] [Google Scholar]
- 39.Chander Roland B, Mullin GE, Passi M, et al. A Prospective Evaluation of Ileocecal Valve Dysfunction and Intestinal Motility Derangements in Small Intestinal Bacterial Overgrowth. Dig Dis Sci 2017;62(12):3525–3535. doi: 10.1007/s10620-017-4726-4 [DOI] [PubMed] [Google Scholar]
- 40.Firrman J, Liu L, Mahalak K, et al. The impact of environmental pH on the gut microbiota community structure and short chain fatty acid production. FEMS Microbiology Ecology 2022;98(5):fiac038. doi: 10.1093/femsec/fiac038 [DOI] [PubMed] [Google Scholar]
- 41.Liu Chen Kiow J, Bellila R, Therrien A, Sidani S, Bouin M. Predictors of Small Intestinal Bacterial Overgrowth in Symptomatic Patients Referred for Breath Testing. J Clin Med Res 2020;12(10):655–661. doi: 10.14740/jocmr4320 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Gabbard SL, Lacy BE, Levine GM, Crowell MD. The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth. Dig Dis Sci 2014;59(3):638–644. doi: 10.1007/s10620-013-2960-y [DOI] [PubMed] [Google Scholar]
- 43.Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Alimentary Pharmacology & Therapeutics. 2011;33(9):1059–1067. doi: 10.1111/j.1365-2036.2011.04625.x [DOI] [PubMed] [Google Scholar]
- 44.Allais L, Kerckhof FM, Verschuere S, et al. Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environmental Microbiology. 2016;18(5):1352–1363. doi: 10.1111/1462-2920.12934 [DOI] [PubMed] [Google Scholar]
- 45.Pavia CS, Pierre A, Nowakowski J. Antimicrobial activity of nicotine against a spectrum of bacterial and fungal pathogens. J Med Microbiol 2000;49(7):675–676. doi: 10.1099/0022-1317-49-7-675 [DOI] [PubMed] [Google Scholar]
- 46.Miller G, Palmer KR, Smith B, Ferrington C, Merrick MV. Smoking delays gastric emptying of solids. Gut 1989;30(1):50–53. doi: 10.1136/gut.30.1.50 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Murthy SN, Dinoso VP, Clearfield HR, Chey WY. Serial pH changes in the duodenal bulb during smoking. Gastroenterology. 1978;75(1):1–4. [PubMed] [Google Scholar]
- 48.Shanahan ER, Shah A, Koloski N, et al. Influence of cigarette smoking on the human duodenal mucosa-associated microbiota. Microbiome. 2018;6(1):150. doi: 10.1186/s40168-018-0531-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Elphick DA, Chew TS, Higham SE, Bird N, Ahmad A, Sanders DS. Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier? Gerontology. 2005;51(6):396–401. doi: 10.1159/000088704 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in a controlled access data storage.
